Abstract Submission Guidelines

DEADLINE: The deadline for electronic submission of abstracts is:

               Monday 3 December 2018


Abstract Title:

  • The title should be brief and reflect the content of the abstract (maximum 25 words)
  • Please use standard UPPER CASE letters 
  • Do not use non-standard abbreviations
  • Commercial names may not be used in the abstract's title (generic names only)
  • Do not put a full stop (.) at the end of the sentence

Number of Abstracts Submitted:

  • Each person may submit up to 3 abstracts as a presenting author. There is no limit to the number of abstracts one person may submit.

 

Abstract Text Length:

  • The abstract may be up to 400 words (Please note: graphs created by using the graph button will count each word). Provide an accurate, succinct, and informative representation of the content that will be presented in the poster, if accepted.

 

Abstract Format:  

  • Introduction; Materials and Methods; Results; Discussion; Conclusions; Learning Objectives and References.

Graphs and Images:

  • These may be uploaded in JPG, PNG and GIF format only. When including a table, it is recommended to save the table as an image and then upload it in to the abstract. Images must be AT LEAST 600 dpi, as lower resolution images will not reproduce well.

Abbreviations:

  • Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the Materials and Methods section only, with an ®, and if in brackets following the generic name, i.e. "generic (Commercial ®)". Do not use the ampersand character (&) unless it is part of the company name.

Language:

  • The abstract must be submitted in good English.  Proofread for typographical, grammar, and syntax errors. The Scientific Committee reserves the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter

 

Authors:

  • Authors should be entered in the order in which they should appear in print.
  • If you (the Submitting Author) are not the Presenting author on an abstract, you will need to send contact information on the Presenting author to the Congress Secretariat.
  • The presenting author can be replaced by one of the abstract co-authors only.
  • The presenting author will become the main point of contact should the abstract be accepted.
  • Oral and poster presentations are limited to one (1) primary presenter.

Institution Affiliations:

  • All department and institutional affiliations should be listed.

 

SUBMITTING YOUR ABSTRACT: 

After you submit your abstract, you can re-enter the submission link at any time to view and edit your abstract until the deadline date. There is no option to save the abstract as draft and to submit it at a later stage. If you do not submit your abstract, the information will be deleted.

  • If after you have submitted your abstract you do not receive the confirmation from the INS 2019 Secretariat, please contact the Congress Secretariat.
  • If you wish to withdraw your abstract, please contact the Congress Secretariat.

 

NOTIFICATIONS: 

Notification of abstract acceptance or non-acceptance will be emailed to the person listed on the abstract as Presenting author in mid-February 2019.

 

Content without Commercial Bias*

The content of abstracts, posters and oral presentations must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Presentations must avoid commercialism and may not contain any logos, commercial branding or messaging.

Abstracts, posters and oral presentations must give a balanced view of therapeutic options. If the content includes trade names, where available, trade names from several companies should be used, not just trade names from a single company, and they should be limited to the material and methods section only. Generic terms contribute to impartiality, and should be used in title and in the body of the abstract.

 

Policy on Commercial Support*

Presentations that constitute promotion and advertising will not be accepted. If the cost of a presentation has been underwritten to any extent, a clear acknowledgement stating the support and identifying the source should be included in the abstract (e.g., "The support of [corporation or institution] for this project is gratefully acknowledged."). Statements made in presentations are the sole responsibility of the author or presenter. Statements should not be viewed as or considered representative of any formal stance or position taken on any subject, issue, or product by the International Neuromodulation Society.

*From ACCME Standards for Commercial Support SM

 

Industry employees' participation as presenters in the scientific program is only allowed if they agree to speak only on completely non-commercial topics, unrelated to any of their company's products, such as:

  - basic science research (e.g. pre-clinical research, or therapy discovery)

 - process or methodologies of research unrelated to a specific disease or device

 - mechanisms of action unrelated to a specific product


Selection Criteria

Submissions will be reviewed and rated by members of the Scientific, Biennial Congress, and Education and CME Committees and Neuromodulation Editorial Board who have expertise in the clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, study design and conflict of interest. Any conflicts of interest must be resolved prior to an abstract's acceptance.

 

*** Submitted abstracts cannot be modified or corrected after the submission                                deadline (Monday, 3 December 2018).***


Keep Me Updated